Loading
Life sciences · Journal article
International Journal of Molecular Sciences · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of the anticancer mechanisms of Cirsium japonicum and its constituents, organized within the Hallmarks of Cancer framework. The evidence is limited to in vitro and preclinical studies, with mechanistic claims based primarily on pathway associations rather than validated target engagement or clinical efficacy. Substantial translational work is required before therapeutic potential can be established.
Narrative review. Intervention: Cirsium japonicum extracts, flavonoid fractions, phenylpropanoid glycosides, nanoparticle formulations, and associated constituent compounds (pectolinarigenin, apigenin, luteolin, acacetin, linarin, cirsimaritin, pectolinarin).
Direct studies of C. japonicum extracts and derivatives demonstrate antitumor, cytotoxic, antiangiogenic, immunomodulatory, and ferroptosis-associated activities, although target-level validation remains limited Pectolinarigenin has the most developed mechanistic evidence, involving RRM2–CDK1, TOP2A, STAT3, and PI3K/AKT/mTOR signaling Six additional constituents (apigenin, luteolin, acacetin, linarin, cirsimaritin, pectolinarin) influence multiple hallmark pathways including regulated cell death, proliferative signaling, angiogenesis, and metastasis
Pharmacokinetic parameters, bioavailability, and in vivo systemic exposure are not characterized Pharmacokinetics, systemic exposure, botanical standardization, tumor selectivity, and clinical relevance remain insufficiently characterized
This review does not provide evidence sufficient to guide clinical practice. Practitioners should regard C. japonicum as an investigational botanical with preliminary mechanistic plausibility but no established efficacy or safety data in humans; clinical trials and validated target engagement studies are needed before clinical application.
A narrative review of mechanistic evidence from in vitro and preclinical studies, lacking clinical trials, efficacy data, or validated targets in humans; raises questions for investigation rather than answering them.
As stated by the source record.
This review does not provide evidence sufficient to guide clinical practice. Practitioners should regard C. japonicum as an investigational botanical with preliminary mechanistic plausibility but no established efficacy or safety data in humans; clinical trials and validated target engagement studies are needed before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cirsium japonicum is a medicinal plant traditionally used in East Asian medicine and contains multiple bioactive constituents with potential anticancer properties. This review critically evaluates the anticancer effects of C. japonicum and its associated constituents within the Hallmarks of Cancer framework. Evidence was classified as direct plant-specific evidence, constituent-based evidence, or contextual mechanistic evidence to distinguish findings obtained using botanical preparations from those generated using purified compounds derived from other sources. Direct studies of C. japonicum extracts, flavonoid fractions, phenylpropanoid glycosides, and C. japonicum var. maackii-mediated gold nanoparticles demonstrate antitumor, cytotoxic, antiangiogenic, immunomodulatory, and ferroptosis-associated activities, although target-level validation remains limited. Among its associated constituents, pectolinarigenin has the most developed mechanistic evidence, involving RRM2–CDK1, TOP2A, STAT3, and PI3K/AKT/mTOR signaling. Apigenin, luteolin, acacetin, linarin, cirsimaritin, and pectolinarin additionally influence regulated cell death, proliferative signaling, angiogenesis, metastasis, immune regulation, metabolic vulnerability, senescence, and therapy response. However, much of this evidence relies on pathway-associated changes rather than direct target engagement or genetic validation. Furthermore, the pharmacokinetics, systemic exposure, botanical standardization, tumor selectivity, and clinical relevance of these compounds remain insufficiently characterized. Future studies should prioritize standardized preparations, quantitative exposure analysis, functional target validation, clinically relevant models, and carefully designed combination strategies. Collectively, C. japonicum provides a promising multi-hallmark framework for anticancer investigation, but substantial translational evidence is still required before its therapeutic potential can be established.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.